Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib

International Journal of DermatologyEarly View Correspondence Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib Lella Asfour BSc, MBChB, MRCP, Corresponding Author Lella Asfour BSc, MBChB, MRCP leila.asfour@srft.nhs.uk orcid.org/0000-0002-0049-8377 Sinclair Dermatology, Melbourne, Victoria, Australia Joint first authors - contributed equally to this paper.Search for more papers by this authorThemis Getsos Colla MBBS, MD, Themis Getsos Colla MBBS, MD Sinclair Dermatology, Melbourne, Victoria, Australia Joint first authors - contributed equally to this paper.Search for more papers by this authorAnthony Moussa MBBS, MS, Anthony Moussa MBBS, MS Sinclair Dermatology, Melbourne, Victoria, AustraliaSearch for more papers by this authorRodney D. Sinclair MBBS, MD, FACD, Rodney D. Sinclair MBBS, MD, FACD orcid.org/0000-0001-6751-1428 Sinclair Dermatology, Melbourne, Victoria, Australia University of Melbourne, Melbourne, Victoria, AustraliaSearch for more papers by this author Lella Asfour BSc, MBChB, MRCP, Corresponding Author Lella Asfour BSc, MBChB, MRCP leila.asfour@srft.nhs.uk orcid.org/0000-0002-0049-8377 Sinclair Dermatology, Melbourne, Victoria, Australia Joint first authors - contributed equally to this paper.Search for more papers by this authorThemis Getsos Colla MBBS, MD, Themis Getsos Colla MBBS, MD Sinclair Dermatology, Melbourne, Victoria, Australia Joint first authors - contributed equally to this paper.Search for more papers by this authorAnthony Moussa MBBS, MS, Anthony Moussa MBBS, MS Sinclair Dermatology, Melbourne, Victoria, AustraliaSearch for more papers by this authorRodney D. Sinclair MBBS, MD, FACD, Rodney D. Sinclair MBBS, MD, FACD orcid.org/0000-0001-6751-1428 Sinclair Dermatology, Melbourne, Victoria, Australia University of Melbourne, Melbourne, Victoria, AustraliaSearch for more papers by this author First published: 20 June 2022 https://doi.org/10.1111/ijd.16316 Conflict of interest: Prof Rodney Sinclair is a current AJD Associate Editor. Prof Sinclair reports being Director and Founder of Samson Clinical Pty Ltd., participates on the pharmaceutical advisory board for Eli Lilly, Pfizer Inc., Leo Pharmaceutical; is on the speakers bureau for Abbvie and Novartis; and is principal investigator in clinical trials for Amgen, Novartis, Arcutis Biotherapeutics, Aerotech, Merck and Co, Celgene, Coherus BioSciences, Jannsen, Regeneron, MedImmune, Glaxo Smith Kline, Samson Clinical, Boehringer Ingelheim, Oncobiologics, Roche, Ascend, Dermira, AstraZeneca, Akesobio, Reistone Biopharma, UCB, Sanofi, Connect, Arena, Sun Pharma, Bristol Myer Squibb, and Galderma. Leila Asfour, Themis Getsos Colla, and Anthony Moussa have no conflict of interest. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Early ViewOnline Version of Record before inclusion in an issue RelatedInformation